AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer

Launched by IRCCS SAN RAFFAELE · Jan 20, 2025

Keywords

ClinConnect Summary

The AI-HOPE Lung Cancer trial is exploring how artificial intelligence can help predict how well patients with advanced non-small cell lung cancer (NSCLC) will respond to specific treatments, such as immunotherapy or a combination of chemotherapy and immunotherapy. By collecting and analyzing various patient information—like test results and imaging—researchers aim to create a reliable scoring system that can help identify patients who may not respond to treatment or those who are likely to survive longer than expected. This could lead to better personalized care and treatment options for patients.

To participate in this study, patients need to be diagnosed with stage IV NSCLC and have received at least one cycle of immunotherapy or chemotherapy. The trial is open to patients aged 65 and older, and both men and women can join. Participants can expect their medical information to be collected over time to help improve the understanding of how different variables affect treatment outcomes. This study is important because it may help doctors tailor follow-up care and suggest alternative treatments for those who need them.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients with histological or cytological diagnosis of NSCLC
• • Stage IV according to investigator's staging procedures (or any locally advanced tumour not feasible for local radical treatment)
• • Treatment with at least 1 cycle of mono-immunotherapy or chemo-immunotherapy (as per clinical practice)
• • Availability of follow-up
• Exclusion criteria:
• • Patients with other thoracic tumours non-NSCLC (i.e. SCLC)
• • Stage other than IV or feasible for radical treatment upfront
• • Treatment within clinical trials (with combination regimens different from the aforementioned combinations)
• • Lost to follow-up